Expert Opinion on Pharmacotherapy最新文献

Statement of Retraction: Combined use of ultra-short acting β-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone. 撤回声明：联合使用超短效β受体阻滞剂艾司洛尔和静脉注射磷酸二酯酶3抑制剂依诺西酮。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-05-08 DOI: 10.1080/14656566.2026.2671545

引用次数: 0

Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitors. 靶向治疗骨髓纤维化贫血及jak抑制剂的影响。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-05-08 DOI: 10.1080/14656566.2026.2671877

Iman Al Noumani, Claire Harrison

{"title":"Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitors.","authors":"Iman Al Noumani, Claire Harrison","doi":"10.1080/14656566.2026.2671877","DOIUrl":"https://doi.org/10.1080/14656566.2026.2671877","url":null,"abstract":"Introduction: Anemia is a hallmark feature of Myelofibrosis (MF), frequently present at diagnosis and almost universal with disease evolution. It is a major contributor to symptom burden, transfusion dependence, healthcare utilization, and adverse prognosis, and is incorporated into contemporary risk stratification models.Areas covered: This review highlights current definitions of MF-associated anemia, including trial and prognostic thresholds, and outlines its incidence, clinical impact, and multifactorial pathophysiology. Therapeutic approaches reviewed include supportive options, differential anemia profiles of JAK inhibitors and emerging targeted strategies like TGF-β ligand traps, hepcidin-pathway modulation, novel agents and combination approaches.Expert opinion: Anemia in MF is a core feature, not just a complication. The shift is from supportive to mechanism-guided therapy targeting iron restriction, erythroid maturation, inflammation, and newer JAK inhibitors with anemia benefits as well as mutation targeted therapy. Unmet needs include standardized endpoints, biologically stratified trials, and validation of hemoglobin and transfusion responses as markers. Strategies like momelotinib plus luspatercept, earlier intervention, and new molecular therapies could turn treatment from palliation to durable control and disease modification.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management. 血小板生成素受体激动剂治疗免疫性血小板减少症：机制、疗效和个性化治疗前景的比较综述。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-05-07 DOI: 10.1080/14656566.2026.2651283

Emmanuel Andrès, Xavier Jannot, Jean Edouard Terrade, Noel Lorenzo-Villalba

{"title":"Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management.","authors":"Emmanuel Andrès, Xavier Jannot, Jean Edouard Terrade, Noel Lorenzo-Villalba","doi":"10.1080/14656566.2026.2651283","DOIUrl":"10.1080/14656566.2026.2651283","url":null,"abstract":"Introduction: Thrombopoietin receptor agonists (TPO-RAs) have reshaped the management of chronic immune thrombocytopenia (ITP) by directly targeting impaired platelet production, a mechanism previously overshadowed by immune-mediated destruction. The three approved agents-romiplostim, eltrombopag, and avatrombopag-all stimulate the c-Mpl receptor but differ in their molecular interactions, pharmacokinetics, and potential immunomodulatory properties.Areas covered: We review classic databases (PubMed, Google Scholar) between 2015 and 2025. We also used Chat GPT and Claude AI to complete the search. We summarize the pharmacological characteristics, mechanisms of action, and clinical profiles of currently available TPO-RAs. We also address individualized treatment strategies for patients with complex comorbidities, refractory disease, or heightened bleeding risk. Emerging evidence supports exploring TPO-RAs earlier in the therapeutic sequence, including selected first-line settings. Additionally, advances in biomarkers, disease monitoring, and the integration of Artificial Intelligence (AI) and Machine Learning (ML) hold promise for refining dose adjustment, predicting response, and improving relapse risk stratification.Expert opinion: TPO-RAs now represent a cornerstone of chronic ITP management and are expected to see broader use as growing evidence supports earlier and more individualized treatment strategies. Future progress will rely on personalized therapeutic strategies, informed monitoring, and AI-driven predictive tools that together may enhance remission durability and long-term clinical outcomes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":2.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating linaclotide for the treatment of functional constipation in children and adolescents. 评价利那洛肽治疗儿童和青少年功能性便秘的疗效。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-05-06 DOI: 10.1080/14656566.2026.2669339

Manuel Linares, Miguel Saps

{"title":"Evaluating linaclotide for the treatment of functional constipation in children and adolescents.","authors":"Manuel Linares, Miguel Saps","doi":"10.1080/14656566.2026.2669339","DOIUrl":"https://doi.org/10.1080/14656566.2026.2669339","url":null,"abstract":"Introduction: Pediatric functional constipation is a highly prevalent disorder associated with significant morbidity and impaired quality of life. Despite widespread use of osmotic and stimulant laxatives, a substantial proportion of children remain symptomatic, highlighting an unmet need for novel therapies.Areas covered: This review provides an overview of the mechanism of action, pharmacokinetics, safety, and clinical efficacy of linaclotide for the treatment of functional constipation in children. Evidence from phase 2 dose-finding studies, a pivotal phase 3 randomized controlled trial, and real-world data is summarized. Prior pediatric experience with other prosecretory and prokinetic agents is discussed to contextualize the current therapeutic landscape. A focused literature review was conducted using PubMed/MEDLINE and regulatory sources (U.S. Food and Drug Administration [FDA]), prioritizing pediatric clinical trials and observational studies evaluating linaclotide in functional constipation.Expert opinion: Linaclotide may represent a mechanism-based therapeutic option for pediatric patients with functional constipation who remain symptomatic despite optimized conventional therapy. By targeting guanylate cyclase-C-mediated epithelial secretion, linaclotide is associated with improvements in bowel habits and a predominantly gastrointestinal safety profile. However, the pediatric evidence base remains relatively limited, and further studies are needed to define long-term outcomes, predictors of response, and its role within treatment algorithms.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.7,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of state-of-the-art pharmacotherapy for malaria in infants: a breakthrough? 最先进的药物治疗对婴儿疟疾的影响：一个突破？

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-05-06 DOI: 10.1080/14656566.2026.2668586

Martin Peter Grobusch, Bayode Romeo Adegbite, Thomas Hanscheid, Nitin Gupta

引用次数: 0

Targeted small molecules in polymyalgia rheumatica: the emerging role of JAK inhibitors beyond glucocorticoids and DMARDs. 靶向小分子在风湿性多肌痛中的作用：jak抑制剂在糖皮质激素和DMARDs之外的新作用。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-05-05 DOI: 10.1080/14656566.2026.2668585

Miguel Ángel González-Gay, Miguel Álvarez-Rubio, Ana de Benito-Vernière, Mariam Belhaj-Gandar, María Roca-Magnet, Esther F Vicente-Rabaneda, Santos Castañeda

{"title":"Targeted small molecules in polymyalgia rheumatica: the emerging role of JAK inhibitors beyond glucocorticoids and DMARDs.","authors":"Miguel Ángel González-Gay, Miguel Álvarez-Rubio, Ana de Benito-Vernière, Mariam Belhaj-Gandar, María Roca-Magnet, Esther F Vicente-Rabaneda, Santos Castañeda","doi":"10.1080/14656566.2026.2668585","DOIUrl":"10.1080/14656566.2026.2668585","url":null,"abstract":"Introduction: Glucocorticoids remain the cornerstone of therapy for polymyalgia rheumatica (PMR), but their long-term use is associated with substantial toxicity. Glucocorticoid-sparing strategies, particularly anti-IL-6 therapies, are now well established. Targeted small molecules such as Janus kinase (JAK) inhibitors have emerged as potential alternatives to reduce glucocorticoid exposure.Areas covered: This narrative review briefly summarizes conventional and biologic therapies in PMR and focuses on JAK inhibitors, particularly baricitinib and tofacitinib. These agents target the JAK/STAT pathway, a key mediator of cytokine-driven inflammation, including IL-6 signaling. Evidence from the BACHELOR and EAST PMR trials, phase II studies and real-world data, indicates that JAK inhibitors rapidly reduce disease activity, inflammatory markers, and glucocorticoid requirements. Baricitinib achieved sustained low disease activity in approximately 78% of patients at 12 weeks without concomitant glucocorticoids, while tofacitinib demonstrated efficacy comparable to glucocorticoids with significant glucocorticoid-sparing effects. .Expert opinion: JAK inhibitors represent promising therapeutic options, particularly for patients with refractory disease or at high risk of glucocorticoid-related toxicity. Although short-term safety appears acceptable, long-term risks, including cardiovascular events, infections, and malignancy, require further evaluation. Ongoing phase III trials will better define their role in achieving remission without systemic glucocorticoid use and in guiding personalized treatment strategies in PMR.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.7,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes. 评估成人2型糖尿病患者每周1次的胰岛素消耗。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-05-04 DOI: 10.1080/14656566.2026.2667324

Akshaya Ramachandran, Jaskaran Batra, Cyrus Desouza

{"title":"Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes.","authors":"Akshaya Ramachandran, Jaskaran Batra, Cyrus Desouza","doi":"10.1080/14656566.2026.2667324","DOIUrl":"10.1080/14656566.2026.2667324","url":null,"abstract":"Introduction: This review summarizes current evidence on insulin efsitora alfa, a novel once-weekly basal insulin developed to simplify therapy in adults with diabetes. Its Fc-fusion molecular design enables a prolonged half-life and a flat pharmacokinetic profile with low variability. Data from the QWINT phase 3 program demonstrate non-inferior glycemic efficacy compared with once-daily basal insulins across type 2 diabetes populations. Reduced injection burden may improve adherence, satisfaction, and diabetes management.Areas covered: This review discusses the molecular structure and pharmacokinetic mechanisms of insulin efsitora alfa, including insulin receptor binding and FcRn-mediated recycling responsible for its extended duration. Efficacy and safety outcomes from pivotal QWINT trials are reviewed, including HbA1c reduction, CGM outcomes, and hypoglycemia risk. Practical considerations such as dosing, titration, and benefits in real-world settings are highlighted. Evidence gaps remain for patients with advanced chronic kidney disease.Expert opinion: Once-weekly insulins such as efsitora and icodec represent major advances in basal therapy. Efsitora's flatter profile may reduce peak-related hypoglycemia, with efficacy comparable to glargine or degludec. Severe hypoglycemia rates are low in type 2 diabetes and more safety data are needed in special populations.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.7,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is bacterial lysate add-on therapy a cost-effective strategy for childhood asthma? Evidence from a Colombian economic model. 细菌裂解物附加治疗是儿童哮喘的成本效益策略吗？来自哥伦比亚经济模式的证据。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-05-04 DOI: 10.1080/14656566.2026.2667331

Jefferson Antonio Buendía, Juan Antonio Buendia Sánchez

{"title":"Is bacterial lysate add-on therapy a cost-effective strategy for childhood asthma? Evidence from a Colombian economic model.","authors":"Jefferson Antonio Buendía, Juan Antonio Buendia Sánchez","doi":"10.1080/14656566.2026.2667331","DOIUrl":"10.1080/14656566.2026.2667331","url":null,"abstract":"Introduction: Despite optimized standard therapy, many children with asthma continue to experience recurrent exacerbations. Bacterial lysates have demonstrated clinical benefits in reducing respiratory infections and asthma exacerbations, but their economic value in low- and middle-income countries remains uncertain. This study evaluated the cost-utility of bacterial lysate add-on therapy compared with standard care in children with mild-to-moderate asthma in Colombia.Methods: A probabilistic Markov decision-analytic model was developed to estimate costs and quality-adjusted life years (QALYs) from a third-payer perspective over a 1-year time horizon. Cost-effectiveness was assessed using a willingness-to-pay threshold of US$5,180 per QALY gained.Results: Bacterial lysate add-on therapy was undominated, with a total cost of US$1,369 and an incremental cost of US$72 compared with standard care. The net monetary benefit was US$3,444 for bacterial lysate add-on therapy versus US$3,361 for standard care.Conclusions: From a probabilistic economic perspective, bacterial lysate add-on therapy appears to be an economically efficient adjunct strategy, with modest individual-level benefits but a high probability of cost-effectiveness within resource-constrained healthcare settings. These findings should be interpreted in the context of model assumptions and the short-term time horizon.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.7,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma. 治疗复发或难治性外周t细胞淋巴瘤的创新方法。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-04-29 DOI: 10.1080/14656566.2026.2667326

Brian T Grainger, Joshua Casan, Chathuri Abeyakoon, Salvia Jain, H Miles Prince

{"title":"Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma.","authors":"Brian T Grainger, Joshua Casan, Chathuri Abeyakoon, Salvia Jain, H Miles Prince","doi":"10.1080/14656566.2026.2667326","DOIUrl":"https://doi.org/10.1080/14656566.2026.2667326","url":null,"abstract":"Introduction: Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of hematologic malignancies arising from mature, post-thymic T- and natural killer (NK) cells. This review explores innovative approaches to managing relapsed or refractory PTCL, emphasizing the need for tailored treatment strategies given the generally poor prognosis associated with these entities.Areas covered: Literature selection followed a comprehensive search of PubMed, MEDLINE and EMBASE up to 2026. The conventional frontline approach remains cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-based chemotherapy. However, the addition of brentuximab vedotin (BV) has improved overall survival (OS) and progression-free survival (PFS) in specific subtypes, particularly anaplastic large cell lymphoma (ALCL). Despite these advances, most patients experience disease relapse or are primary refractory, highlighting a persistent unmet clinical need. Allogeneic stem cell transplantation (allo-SCT) offers curative potential for selected patients, but biological and logistical barriers constrain its wider application.Expert opinion: These advances support a shift toward a more personalized management strategy, prioritizing immunotherapies, epigenetically directed therapies, and small-molecule inhibitors, tailored to disease subtype. By outlining current challenges and emerging treatment modalities, we aim to guide clinicians in optimizing care for this patient population.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":2.7,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapy options and drug development in bronchiectasis: spotlight on dipeptidyl-peptidase inhibitors. 支气管扩张的药物治疗选择和药物开发：聚焦于二肽基肽酶抑制剂。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-04-28 DOI: 10.1080/14656566.2026.2664617

Chiara Premuda, Andrea Gramegna, Sofia Misuraca, Federica Piedepalumbo, Leonardo Terranova, Martina Santambrogio, Martina Contarini, Margherita Ori, Francesco Blasi

{"title":"Pharmacotherapy options and drug development in bronchiectasis: spotlight on dipeptidyl-peptidase inhibitors.","authors":"Chiara Premuda, Andrea Gramegna, Sofia Misuraca, Federica Piedepalumbo, Leonardo Terranova, Martina Santambrogio, Martina Contarini, Margherita Ori, Francesco Blasi","doi":"10.1080/14656566.2026.2664617","DOIUrl":"https://doi.org/10.1080/14656566.2026.2664617","url":null,"abstract":"Introduction: In recent years, the central role of inflammation in the development and persistence of the vicious vortex of bronchiectasis has become increasingly evident, gradually reshaping the therapeutic landscape. Historically, treatment strategies have focused mainly on controlling infection, alleviating symptoms, and enhancing mucociliary clearance. However, accumulating evidence indicates that targeting the inflammatory component represents an important complementary strategy in bronchiectasis management.Areas covered: Within this evolving framework, novel anti-inflammatory approaches are emerging, including the inhibition of dipeptidyl peptidase-1 (DPP-1) which can reduce neutrophil-driven airway inflammation and, consequently, exacerbations. The recent regulatory approval of brensocatib, a DPP-1 inhibitor, represents a milestone in the development of targeted therapies for bronchiectasis.This review provides a narrative overview of available treatments for bronchiectasis, with a particular focus on DPP-1 inhibitors, and discusses their potential role and integration into clinical practice.Expert opinion: The emergence of DPP-1 inhibitors reflects a paradigm shift in bronchiectasis care. While promising, their role remains to be fully defined due to a lack of long-term real-world evidence and comparative studies against established strategies. A major challenge will be identifying the patients most likely to benefit. Despite uncertainties, these agents have the potential to redefine treatment for this complex disease.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.7,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0